MENU

ACRS Stock Aclaris Therapeutics (ACRS, $1.26) entered Downtrend as Momentum indicator drops below 0 level on May 09, 2025

A.I.dvisor
at Tickeron.com
Loading...
ACRS - Aclaris Therapeutics
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $1.26
Daily change: -$0.05 (-3.82%)
Daily volume: 524.2K
Industry: Biotechnology
This indicator may be signaling that ACRS's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 91 similar cases where ACRS's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

ACRS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for ACRS turned positive on April 22, 2025. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRS as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ACRS broke above its upper Bollinger Band on April 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ACRS entered a downward trend on April 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.917) is normal, around the industry mean (14.420). P/E Ratio (0.000) is within average values for comparable stocks, (65.047). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (6.184) is also within normal values, averaging (254.920).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ACRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of novel dermatological therapies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
701 Lee Road
Phone
+1 484 324-7933
Employees
91
Web
https://www.aclaristx.com